New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Bre... (the study includes patients being admini...)

HOME >> MEDICINE >> TECHNOLOGY

New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer

Date:5/29/2009

the study includes patients being administered neratinib (160 mg or 240 mg) daily plus weekly trastuzumab (4 mg/kg IV loading dose then 2 mg/kg). In the second part of the study, patients receive a weekly dose of trastuzumab with daily neratinib (240 mg).

To date, 45 patients have been enrolled and 28 patients were evaluable for efficacy. The 16-week PFS rate (for part 2) was 45 percent (95 percent CI, 26 percent to 62 percent); median PFS was 16 weeks (95 percent CI, 15 to 31 weeks). The complete response rate was 7 percent, while 21 percent of evaluable patients showed partial response. The objective response rate was 29 percent (95 percent CI, 13 percent to 49 percent).

In this study, adverse events of any grade were diarrhea, nausea, anorexia, vomiting, asthenia, rash and fatigue. In the 45 patients enrolled in this study, diarrhea was the most common adverse event, observed in 91 percent of patients, and was the most significant grade 3 or 4 adverse event, occurring in 16 percent of patients. Two patients receiving neratinib 240 mg reported adverse events leading to discontinuation of therapy.

Safety and Efficacy of Neratinib (HKI-272) in Combination with Paclitaxel in Patients with Solid Tumors

In a separate phase 1/2, open-label, 2-part study, ascending multiple daily oral doses of neratinib (160 mg, 240 mg) were administered in combination with IV paclitaxel 80 mg/m2, if tolerable, or 70 mg/m2 on days 1, 8 and 15. Patients with solid tumors (endometrial, cervical, colorectal and esophageal cancers) were entered in the phase 1 portion (part 1), and only patients with metastatic ErbB-2 positive breast cancer were enrolled in part 2. Safety and efficacy were investigated in patients with ErbB-2 positive metastatic breast cancer.

A total of 102 patients were enrolled in part 2 of the study and 97 patients were evaluable for efficacy. The overall
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
2. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
3. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
4. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
5. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
6. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
7. Neuronetrix Announces Preliminary Alzheimers Study Results at the Society for Neuroscience Conference
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Preliminary Data From Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa
10. What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study
11. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

Post Your Comments:

(Date:6/18/2013)... 18, 2013 Remedy Informatics, a leading ... life sciences research, today announced it has been ... Schedule 70 supply contract (GS-35F-367AA, effective May 7, ... IT solutions to government agencies at federal, state ... Remedy has placed its products and services on ...

(Date:6/18/2013)... , June 18, 2013 Pro football player and ... and professional family expert Jo Frost have ... Specialty L.P., the fully integrated specialty pharmaceutical business of ... awareness of this significant health problem. In recognition of ... and Drug Administration (FDA) approval of EpiPen ® ...

(Date:6/17/2013)... ANGELES , June 17, 2013 Velplex, ... TopProdeals.com , a technology platform that connects buyers and ... into being an industry leader. Why? ... at TopProdeals™ are intimately familiar with the dental industry. ... healthcare community and have diligently worked to negotiate some ...

Breaking Medicine Technology:Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2 Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3 Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4 Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 2 Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 3 Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 4 Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 5 Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 6 Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 7 Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 8 TopProdeals.com Rises to Top as Discount Dental Supply Leader 2

[0] Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies [0] Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign [0] TopProdeals.com Rises to Top as Discount Dental Supply Leader

... Resources, one of the world,s leading research and advisory ... insulins and insulin analogues stand to erode $6.1 billion ... Germany, Italy, Spain and U.K.) by 2018, saving healthcare ... insulins are relatively easy to develop and manufacture, the ...

... , WASHINGTON, Oct. 14 The exhibit hall at ... E. Washington Convention Center is brimming with displays of ... of research and development in the MedTech industry, and ... care of people all over the world. The ...

Cached Medicine Technology:Biosimilar Insulins and Insulin Analogues Stand to Erode $6.1 Billion in Brand Sales in the U.S. and Europe by 2018 2 Biosimilar Insulins and Insulin Analogues Stand to Erode $6.1 Billion in Brand Sales in the U.S. and Europe by 2018 3 Vibrant Exhibit Hall Features Innovative Medical Technology at AdvaMed 2009 2

(Date:6/18/2013)... shown that cancer cells have a much different ... scientists at The University of Texas at Dallas have ... strategy to combat lung cancer. , In an article ... ONE , UT Dallas researchers compared the metabolic characteristics ... taken from the same patient. , They found ...

(Date:6/18/2013)... new commercial venture, using technology developed at Case ... and Case School of Engineering, has made available ... allows graduate students and others training to evaluate ... program, reducing stress on the trainee, because a ... real person. , Graduate students studying to ...

(Date:6/18/2013)... June 18, 2013 More than 1.1 million ... with HIV/AIDS, according to the Centers for Disease Control and ... are infected. In support of National HIV Testing Day on ... Disability Insurance (SSDI) representation, the CDC and other organizations ... , The CDC reports about 50,000 new HIV infections each ...

(Date:6/18/2013)... 2013 The Elizabeth Glaser Pediatric AIDS ... the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) ... new milestones in the global effort to eliminate pediatric ... that as of June 2013, one million babies globally ... Since PEPFAR’s inception in 2003, EGPAF has been a ...

(Date:6/18/2013)... 2013 Two months ago, Suyima Torres, 28, ... for a second session of a silicone treatment for gluteus ... treatment was allegedly performed by a mystery Venezuelan doctor in ... According to Dr. Bernabe Vazquez of Bayshore Cosmetic Surgery ... from doctor’s who are not board certified is more common ...

Breaking Medicine News(10 mins):Health News:UT Dallas study suggests new approach to fight lung cancer 2 Health News:UT Dallas study suggests new approach to fight lung cancer 3 Health News:SimuCase avatars advance speech-language pathology training 2 Health News:Allsup Observes National HIV Testing Day June 27 2 Health News:Allsup Observes National HIV Testing Day June 27 3 Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2 Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3 Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2 Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3

[0] UT Dallas study suggests new approach to fight lung cancer [0] SimuCase avatars advance speech-language pathology training [0] Allsup Observes National HIV Testing Day June 27 [0] One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS [0] Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection

... the first FDA approval of a PEGylated Fab, fragment of ... humanized ... Food and,Drug Administration (FDA) approved UCB,s Cimzia(R) (certolizumab pegol) for,reducing ... in adult patients with moderate to severe active disease who ...

... PALO ALTO, Calif., April 23 Jazz,Pharmaceuticals, Inc. ... Cozadd, the,company,s Executive Chairman, will provide a corporate ... in Key Biscayne, FL,on May 1, 2008 at ... of the presentation may be accessed by visiting ...

... Information Technology to Meet Today,s Healthcare Challenges, ... Quantum Group,Inc. (AMEX: QGP, QGP.WSA, QGP.WSB) ... CEO, Noel J. Guillama has been asked ... Corporation,s 7th Annual Life,Science Conference, "Leveraging Information ...

... - Treat Yourself to EDY,S Winning American Idol Ice Cream and, Limited-edition ... ... Cause -, BOSTON, and OAKLAND, Calif., April 23 Everyone,s a,winner ... Day on Saturday, May 3 for the Triple Winner Game,Scoop(R) Day event., ...

... increased 18% to $1.09; ... fiscal year, FRANKLIN LAKES, N.J., April 23 ... reported record quarterly revenues,of $1.747 billion for the second ... 11 percent over the prior year period. This,quarter,s revenue ...

... Superior court dismisses illegal temporary restraining order ... publicity stunt, OAKLAND, Calif., April 22 ... order against the,Service Employees International Union (SEIU) and ... publicity stunt by the California Nurses Association,(CNA). The ...

FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform Jazz Pharmaceuticals to Present at Morgan Stanley Conference The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference EDY'S(R) Slow Churned(R) and Stop & Shop Stores Announce Scoop Day With Sweet Deals to Support the Fight Against Childhood Cancer BD Announces Results for Second Fiscal Quarter Court Throws Out Restraining Order Against SEIU

... GORE SEAMGUARD® Bioabsorbable Staple Line ... procedures in which soft tissue transection ... is needed.,The GORE SEAMGUARD Bioabsorbable Staple ... easy-to-use material for reinforcement of staple ...

... for temporary wound support. Especially suitable ... stretchable support material is desired and ... required. Predictable absorption. Polyglactin 910 has ... and nonpyrogenic. ,VICRYL (polyglactin 910) knitted ...

Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....

... Biosurgical Composite is designed for the repair ... PPM mesh that has two distinct sides. ... coated with a layer of sodium hyaluronate ... Adhesion Barrier). This coated side is bioresorbable, ...

Medicine Products:

GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement Material VICRYL (polyglactin 910) knitted mesh Surgisis® ES Soft Tissue Grafts Sepramesh Biosurgical Composite